Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year Low - Time to Sell?

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $8.95 and last traded at $9.15, with a volume of 1016238 shares changing hands. The stock had previously closed at $9.34.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RCUS shares. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their target price for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. Morgan Stanley lowered their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Finally, Bank of America lowered their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $30.25.

Arcus Biosciences Trading Down 1.4 %

The business's 50 day moving average price is $11.77 and its 200-day moving average price is $14.68. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The company has a market cap of $940.46 million, a price-to-earnings ratio of -2.84 and a beta of 1.36.

Remove Ads

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $36.00 million during the quarter, compared to analysts' expectations of $29.38 million. On average, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Terry J. Rosen bought 19,800 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the acquisition, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company's stock.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after buying an additional 833 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Arcus Biosciences by 2.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company's stock valued at $471,000 after buying an additional 843 shares during the period. JPMorgan Chase & Co. increased its holdings in Arcus Biosciences by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after buying an additional 1,117 shares during the period. R Squared Ltd bought a new position in Arcus Biosciences in the 4th quarter valued at about $26,000. Finally, Teacher Retirement System of Texas increased its holdings in Arcus Biosciences by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after buying an additional 2,410 shares during the period. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.